ALK and non-small cell lung carcinoma: Following the international guidelines, the standard of care in Qatar is to manage metastatic adenocarcinoma NSCLC patients with platinum-based regimens plus pemetrexed as the first line, followed by taxanes-based regimen on progression and then to target the EGFR or ALK mutations with the appropriate available formulary tyrosine kinase inhibitor (TKI).